Novavax Stock Climbs Monday: What's Going On?

Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor

Novavax is rising on investors reaction to an unconfirmed rumor that Matrix-M has a favorable safety profile with self-limiting side effects.

Novavax shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.

Watching Novavax; Shares Trading Higher In The Session, Traders Circulate Unconfirmed Rumor Suggesting Clinical Data Show That Matrix-M Has A Favorable Safety Profile With Mostly Mild-To-Moderate, Self-Limiting Side Effects

What's Going On With Novavax Stock?

Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot toward licensing and cost-structure optimization.

PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company

PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.